The interest in the potential therapeutic use of cannabis, especially cannabidiol (CBD), has increased significantly in recent years. On the Internet, users can find lots of articles devoted to its medical features such as reducing seizure activity in epilepsy. The aim of our work was to evaluate the information contained on the websites, including social media, in terms of the credibility and the reliability of current knowledge about the usage of products containing cannabidiol in epilepsy treatment. We used online available links found using the Newspointtool. The initial database included 38,367 texts, but after applying the inclusion and exclusion criteria, 314 texts were taken into consideration. Analysis was performed using the DISCERN scale and the set of questions created by the authors. In the final assessment, we observed that most of the texts (58.9%) were characterized by a very poor level of reliability and the average DISCERN score was 26.97 points. Additionally, considering the form of the text, the highest average score (35.73) came from entries on blog portals, whereas the lowest average score (18.33) came from comments and online discussion forums. Moreover, most of the texts do not contain key information regarding the indications, safety, desired effects, and side effects of CBD therapy. The study highlights the need for healthcare professionals to guide patients towards reliable sources of information and cautions against the use of unverified online materials, especially as the only FDA-approved CBD medication, Epidiolex, differs significantly from over-the-counter CBD products.

Hypoglycemic encephalopathy (HE) is a type of encephalopathy resulting from extremely low blood glucose level. Symptoms are not specific and can be misdiagnosed very often. It can occur during deep and/or prolonged hypoglycemia, which may be a result of inadequately controlled diabetes. Here,...

Background: Crisponi/cold-induced sweating syndrome (CS/CISS) is a rare autosomal recessive disorder characterized by severe neonatal manifestations including paroxysmal muscle contractions, tendency for hyperthermia, and feeding and swallowing difficulties with high neonatal mortality. Pathogenic variants in the Cytokine Receptor-Like Factor 1 (CRLF1) gene have been associated with CS/CISS. These variants result in a loss of function of the encoded protein, which disrupts the formation of a functional heterodimer with Cardiotrophin-Like Cytokine Factor 1 (CLCF1). This complex is essential for the development of autonomic and sensory nervous systems, as well as for bone remodeling. We report two patients affected by CS harboring pathogenic variants in the CRLF1 gene. Methods—case reports: The first patient was diagnosed postnatally, presenting with non-epileptic paroxysmal events characterized by opisthotonus and orofacial contractions. He survived beyond infancy, later developing scoliosis and persistent episodes of hyperthermia. In the second patient, a prenatal ultrasound at 20 weeks of gestation revealed bilateral camptodactyly, also referred to as the ‘horn’s sign’, raising early suspicion of CS. The diagnosis was subsequently confirmed both clinically and genetically. After birth, the infant developed severe dysphagia, apnea, and paroxysmal events not associated with epileptiform activity on EEG. Sanger sequencing identified a homozygous c.708_709delinsT frameshift variant in the CRLF1 gene. The patient died at 30 days of age due to respiratory failure. Results and conclusions: With this manuscript, we aim to further delineate the phenotypic spectrum of this rare condition and propose the ‘horn’s sign’ as a targeted prenatal marker for early diagnosis in populations with known founder mutations or familial risk factors.

Introduction: Dynamic technological progress has contributed to significant advances in the field of Artificial Intelligence (AI). Its potential is already being used in many aspects of life, including medicine. The aim of this article was to focus on analyzing the effectiveness of AI-based language models in the context of tackling the Polish State Specialisation Examination (SSE) in paediatric neurology. Material and methods: The study evaluated the effectiveness of two language models i.e., Chat GPT 3.5 and Chat GPT 4.0 in solving two past papers of SSE in paediatric neurology, i.e., those set in spring and autumn 2023. The point scores of both models were compared to the results of physicians taking the SSE at these two sessions. For the study, questions were divided into six thematic groups. Results: Chat GPT 4.0 achieved a pass score (60%) in both examination sessions. Considering the total points obtained in both examination sessions, Chat GPT 4.0 achieved similar scores (72%) to physicians (74%). Significant differences were demonstrated between the results achieved by the older (48%) and newer (72%) versions of Chat GPT. Conclusions: The results presented in our study may indicate the potential utilization of artificial intelligence in the practice of paediatric neurologists. Despite promising results, the use of AI in medicine poses serious ethical and practical challenges for physicians. Our article emphasizes the importance of further research on the use of AI in paediatric neurology and the need for continuous assessment and development of these technologies, raising issues regarding their potential applications and challenges associated with their implementation in clinical practice. Keywords: child neurology artificial intelligence AI Chat GPT